je.st
news
Tag: lung
Pfizer to test Xalkori lung cancer drug with Merck immunotherapy
2014-08-26 18:11:28| Biotech - Topix.net
Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in the hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy.
UPDATE 1-FDA approves use of Eliquis to treat leg, lung clots
2014-08-21 22:53:00| Biotech - Topix.net
Bristol-Myers Squibb Co and Pfizer Inc on Thursday said U.S. regulators have approved an expanded use for their Eliquis blood clot preventer, to treat blood clots in the legs and lungs.
GSK gets a lift as Express Scripts reinstates lung drug Advair
2014-08-04 19:14:18| Biotech - Topix.net
The British company's business has suffered since January after the inhaled medicine Advair was dropped from various formulary lists - including that of Express Scripts - while it fights growing price competition from rival products.
Tags: express
drug
scripts
lift
Waste Management Partners with Lung Association for Hauler CNG Conversion
2014-06-09 15:35:00| Waste Age
Waste Management Inc. has partnered with the American Lung Association and the U.S. Environmental Protection Agency (EPA) to convert seven diesel engine waste haulers to compressed natural gas (CNG). read more
Tags: management
partners
association
waste
First Presentation of Data for Pembrolizumab, Mercks Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014
2014-06-02 13:30:00| Merck.com - Corporate News
Dateline City: CHICAGO Initial Therapy with Pembrolizumab Demonstrates Robust Anti-Tumor Activity with Tumor Shrinkage in 80 Percent of Evaluable PD-L1 Positive, Advanced NSCLC Patients Merck Initiating Phase 3 Study with Pembrolizumab Versus Platinum-Based Doublet Chemotherapy as First-Line Therapy in PD-L1 Positive, Advanced NSCLC (KEYNOTE-024) Additional 50 Patients Enrolled in KEYNOTE-001 with Analyses Planned Using Mercks Proprietary PD-L1 Assay at One Percent and 50 Percent Cut Points CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of data evaluating pembrolizumab (MK-3475), Mercks investigational anti-PD-1 antibody, as initial therapy in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia Contacts:Ian McConnell, (973) 901-5722orClaire Mulhearn, (908) 423-7425orInvestor Contacts:Carol Ferguson, (908) 423-4465orJustin Holko, (908) 423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
cell
presentation
Sites : [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] next »